Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Cancer -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (3)	3/31/2001 4:32:49 PM
From: Spekulatius	Read Replies (1) \| Respond to of 1840

SUPG -Rubitecan news Wednesday March 28, 9:15 am Eastern Time Press Release SOURCE: SuperGen Inc. Studies Show SuperGen's Rubitecan Has Anti-Tumor Activity Against Melanoma, Prostate and Lung Cancers Data presented at annual meeting of American Association for Cancer Research (AACR) DUBLIN, Calif., March 28 /PRNewswire/ -- SuperGen Inc. (Nasdaq: SUPG & SUPGZ) announced today that its novel drug compound, rubitecan -- which is now in the final stages of Phase III clinical testing as an oral therapy against pancreatic cancer -- showed anti-tumor activity against melanoma, prostate cancer and lung cancer, in three separate studies. Data from three studies was recently presented at the 92nd Annual Meeting of the American Association for Cancer Research in New Orleans. The first study, under lead investigator Dr. Devasis Chatterjee of Brown University, Providence, R.I., concluded that raf kinase inhibitory protein (RKIP), when added to 9-NC (rubitecan), plays an integral function ``in the sensitization of 9-NC responsive and resistant prostate cancer cells to apoptosis induction (cell death).'' The second study, under lead investigator Dr. Howard Sands of Morrisville, N.C.-based Piedmont Research Center, showed that a proprietary intravenous formulation of 9-NC (rubitecan) had ``outstanding antitumor activity against human melanoma xenografts in nude mice. Furthermore, we now are investigating whether the I.V. activity of 9-NC extends to other human tumor xenografts, and how its spectrum of activity compares to that of oral preparation.'' The third study, under lead investigator Dr. Nadezhda V. Koshkina of Baylor College of Medicine, Houston, demonstrated that an inhaled liposome formulation of 9-NC (rubitecan) and paclitaxel drugs resulted in ``significantly higher concentrations of 9-NC and paclitaxel'' in the lungs of treated mice. Our findings support the continued evaluation of more effective methods for lung cancer treatment by using an aerosol delivery system,`` concluded Dr. Koshkina. Inhaled rubitecan is currently in Phase I/II clinical development. Also presented at AACR were results from a preclinical study showing that SuperGen's anticancer compound decitabine increased the gene expression of four lung cancer cell lines, thus significantly lowering their growth rates. Decitabine, which has a unique mechanism of action - the hypomethylation of DNA - is in Phase III clinical development for myelodysplastic syndrome and Phase I/II clinical development for stage IV non-small cell lung cancer, as well as and sickle cell anemia. Based in Dublin, California, SuperGen is a pharmaceutical company dedicated to the development and commercialization of products intended to treat life-threatening diseases, particularly cancer. This press release contains ``forward-looking'' statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements, including those regarding the clinical development of rubitecan and decitabine, involve certain risks and uncertainties associated with an emerging pharmaceutical company actively involved in clinical trials. Actual results could differ materially from those projected in the ``forward-looking'' statements as a result of failure to obtain the clinical data necessary to support marketing approval of rubitecan and decitabine, as well as other risk factors discussed in SuperGen's reports in file with the U.S. Securities and Exchange Commission (including, but not limited to the report on Form 10-K for the fiscal year ended December 31, 2000) Contact: L. Robert Cohen Vice President, Investor Relations & Finance SuperGen Inc. 800-353-1075, ext. 111 SOURCE: SuperGen Inc.

To: nigel bates who wrote (3)	3/31/2001 4:41:22 PM
From: Spekulatius	Respond to of 1840

Nigel, you are right. Posting the press releases itself is preferable to postings links. Specifically yahoo links expire fairly quickly. I am starting to follow SUPG again. I have been in this stock in 1999 for a little and its looking cheap now. I am not that optimistic about alround chemotherapy drugs since I believe that the future in chemotherapy is with targeted drugs (IMGN, TELK's 286, Bexxar etc.). However, Rubitecan is an oral drug and seems to have a more begnin side effects, which could distinguish it from other chemotherapy drugs.